Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aducanumab→

Aducanumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1384260-65-4
Molecular formula
C6472H10028N1740O2014S46
Molecular weight
145910.4 g/mol
Drug class
Anti-amyloid beta (Aβ) human monoclonal IgG1 antibodyhistorical Alzheimer disease disease-modifying biologic
Mechanism of action
Binds aggregated soluble and insoluble amyloid beta, including oligomers and fibrils, promoting reduction of amyloid plaque burden. This is the pharmacological rationale; clinical benefit was not established to the level required for continued approval.
Indications / reported uses
  • Historical US indication: treatment of Alzheimer disease initiated in patients with mild cognitive impairment or mild dementia stage, following confirmation of amyloid pathology. Aduhelm was withdrawn from clinical use and its US approval was withdrawn on 1 November 2024; it is not a current treatment option.

Sources: NCBI Bookshelf — Aducanumab (Aduhelm) status and withdrawal · FDA — Aduhelm prescribing information (historical label) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aducanumab Environmental Risk Assessment (ERA) (the Aducanumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.